Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Common gastrointestinal side effects include nausea, diarrhoea, vomiting, and dyspepsia, typically most prominent during initial treatment
Tara *Based on internal survey 416 GLP-1 users in 2025 **Based on survey responses of 166 participants in a 6-month clinical trial who had overweight or obesity, and were taking semaglutide/tirzepatide for weight loss within the WW Clinic Program and participating in the GLP-1 companion nutrition program
Improved glycemic control
Understanding these connections empowers individuals to make informed choices about their health and well-being, potentially reducing the occurrence of palpitations in their daily lives
The discussion below combines findings from the 2025 KFF Employer Health Benefits Survey with insights gained from interviews and group discussions with employers from five focus groups across the United States covering over one hundred companies employing over a quarter of a million
